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Chronic Intestinal Inflammatory Condition
Generates IL-10-Producing Regulatory B Cell
Subset Characterized by CD1d Upregulation
(Ozaki et al., 1999; Gonnella et al., 2001) and suppression
of experimental autoimmune encephalomyelitis (Wolf et
al., 1996). Interestingly, even in the rheumatoid arthritis
model in which Igs are required for the development of
the disease, the presence of regulatory B cells has also
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effector and regulatory B cells can coexist. Recently,Bowel Disease
B cell subsets (termed B effector [Be] 1 and Be 2 cells)Massachusetts General Hospital
that possess distinct cytokine production profiles haveBoston, Massachusetts 02114
been identified (Harris et al., 2000).3 Gastroenterology Division
One of the regulatory cytokines is IL-10. IL-10 helpsDepartment of Medicine
preserve immune balance and suppresses the develop-Brigham and Women’s Hospital
ment of autoimmune diseases, including intestinal in-4 Department of Pathology
flammation (de Waal Malefyt et al., 1992; Davidson et5 Department of Medicine
al., 1996). IL-10 is not only involved in the prevention ofHarvard Medical School
Th1 polarization (Asseman et al., 1999) but also inhibitsBoston, Massachusetts 02115
Th2 responses (Grunig et al., 1997; Cottrez et al., 2000).
In addition, IL-10 directly suppresses macrophage/
monocyte-induced inflammatory responses, includingSummary
the release of proinflammatory cytokines (Fiorentino et
al., 1991; O’Farrell et al., 1998; Riley et al., 1999). TheB cells possess a variety of immune functions that are
regulatory T cell subset producing IL-10 suppresses theinvolved in normal and abnormal immune responses,
development of experimental intestinal inflammationincluding autoimmune disorders. Through murine
(Asseman et al., 1999). Although IL-10 is produced bymodels of intestinal inflammation, we here demon-
numerous cell types including B cells, it is unclearstrate a B cell subset that is induced in gut-associated
whether IL-10 produced by B cells plays an importantlymphoid tissues and is characterized by CD1d upreg-
role in the suppression of inflammatory immune re-ulation. This B cell subset appears under a chronic
sponses.inflammatory environment, produces IL-10, and sup-
CD1d molecules are cell surface glycoproteins con-presses progression of intestinal inflammation by
sisting of a heavy chain in noncovalent association withdownregulating inflammatory cascades associated
a 2-microglobulin light chain (Bleicher et al., 1990).with IL-1 upregulation and STAT3 activation rather
The presence of two deep hydrophobic pockets in thethan by altering polarized T helper responses. This
groove of CD1d confers a unique capacity for this mole-study indicates that B cells, by producing cytokines
cule to bind and present certain glycolipid antigens tosuch as IL-10, can act as regulatory cells in immuno-
distinct T cell subsets (Moody et al., 1999). Interestingly,logically mediated inflammatory reactions.
the cytoplasmic tail of CD1d is linked to signaling cas-
cades associated with the transcription of IL-10 (ColganIntroduction
et al., 1999). CD1d is expressed on a wide variety of cell
types, including B cells (Blumberg et al., 1991; BrossayImmune responses are regulated by the cooperative
et al., 1997). In the spleen, an increased expression of
activities of cells that possess diverse immune func-
CD1d (CD1high) has been found in certain subsets of
tions. Functionally distinct subsets have been clearly
B cells, the marginal zone B cells (Amano et al., 1998),
defined in T cells (Abbas et al., 1996; O’Garra, 1998). and the recently identified CD21high(hi)IgMhi B cell subset,
Among these subsets, regulatory T cell subsets down- termed as transitional B cells of type 2 (T2 B cells) (Loder
regulate immune responses for both foreign and self- et al., 1999). The glycolipids presented by CD1d rapidly
antigens and effectively participate in the suppression activate natural killer T (NKT) cells (Bendelac et al., 1997),
of autoimmune disorders (Chen et al., 1994; Asano et and this activation of NKT cells has been reported to
al., 1996; Asseman et al., 1999; Shevach, 2000). B cells be associated with suppression of insulin-dependent
possess a variety of immune functions, including the diabetes (Lehuen et al., 1998) and intestinal inflamma-
production of immunoglobulins (Igs) and cytokines, the tion induced by dextran sodium sulfate (DSS) (Sauber-
presentation of antigens, and the regulation of dendritic mann et al., 2000). In addition, an NKT cell-independent
cell function (Wolf et al., 1996; Moulin et al., 2000; Harris role of CD1d in immune modulation has been recently
et al., 2000). Functionally distinct roles of B cells have demonstrated (Dao et al., 2001). Although CD1d-medi-
also been reported in autoimmune diseases. B cells ated activation of B cells has been reported (Zeng et
drive the development of several autoimmune disorders al., 2000), the functional role of B cells activated by
through the production of pathogenic Igs (Korganow et CD1d-associated pathways is not well characterized.
al., 1999; Fagarasan et al., 2000). On the other hand, Draining lymph nodes are important sites for modulat-
B cells participate in the induction of immune tolerance ing immune responses to foreign and self-antigens (Toh
et al., 2000). Mesenteric lymph nodes (MLN), which are
a part of the gut-associated lymphoid tissue (GALT),6 Correspondence: amizoguchi@partners.org
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participate in maintaining a balance between oral toler- diseased IL10KO mice (FMC106.29.2, n 9) (Figure
1B). To examine whether the upregulation of CD1d onance and active immune responses to intestinal luminal
antigens (Hershberg and Mayer, 2000). Lymphocytes MLN B cells was associated with the development of
intestinal inflammation, age-matched TCRKO mice (6sensitized in the intestine and intestine-derived den-
dritic cells efficiently migrate to MLN (Huang et al., 2000), months of age) with and without intestinal inflammation
were examined. There was significant difference (p and T cells from MLN of some murine colitis models are
capable of transferring the disease into immunodeficient 0.001) of CD1d expression of MLN B cells between
TCRKO mice with and without colitis; upregulation ofrecipient mice (Hollander et al., 1995; Mizoguchi et al.,
1996). An increased translocation of nonpathogenic CD1d was detected on MLN B cells of TCRKO mice
with colitis (FMC  210.5  22.4, n  19) but not inbacteria from the intestinal lumen to MLN is associated
with the development of intestinal inflammation (Dom- TCRKO mice without colitis (FMC  108.7  6.0, n 
11) (Figure 1C). Upregulation of CD1d on B cells was alsobrowicz et al., 2001). It is now generally accepted that
dysregulated immune responses driven by enteric bac- detected in the colonic LP but not the Peyer’s patches
and appendix lymphoid follicle of diseased TCRKO miceteria lead to the development of spontaneous intestinal
inflammation in murine models of colitis (Bhan et al., compared to WT mice (Figure 1D and data not shown).
Since CD1hi B cells have been found among the T2 B cell1999; Blumberg et al., 1999). The T cell receptor knock-
out (TCRKO) mouse, which spontaneously develops subset (Loder et al., 1999) and marginal zone B cells
(Amano et al., 1998) in the spleen, splenic B cells werechronic intestinal inflammation, exhibits a marked
expansion of B cells, especially in MLN. As a result, the also examined. There was no difference in the number
and proportion of splenic CD1hi B cell subsets betweenpathogenic role of B cells was initially postulated to be
responsible for intestinal inflammation observed in these WT mice and diseased TCRKO mice (Figure 1E and
data not shown). As previously described (Amano etmice (Mombaerts et al., 1993; Mizoguchi et al., 1996).
However, subsequent studies using B cell-deficient al., 1998; Loder et al., 1999), the splenic marginal zone
CD1dhi B cells were phenotypically characterized byTCR double-knockout (DKO) mice demonstrated a
regulatory role for B cells in the pathogenesis of this CD21hiCD62hiIgMhiCD23. In contrast, the MLN CD1dhi
B cells were CD21intermediate(int)CD62lowIgMintCD23hi (Figureintestinal inflammation (Mizoguchi et al., 1997, 2000).
The intestinal inflammation also spontaneously devel- 1F and data not shown). These findings indicate that
increased expression of CD1d on B cells of MLN andops in IL-2 knockout (IL2KO) mice and IL-10 knockout
(IL10KO) mice. However, B cells are not required for the colonic LP, but not spleen, is associated with the devel-
opment of intestinal inflammation in TCRKO mice.development of intestinal inflammation in these mice
(Ma et al., 1995; Davidson et al., 1996).
In this study, we have provided evidence to indicate CD1d Participates in the Suppression of Intestinal
that upregulation of CD1d expression under chronic in- Inflammatory Progression
flammatory conditions confers on B cells an ability to To define the role of CD1d in the pathogenesis of intesti-
suppress the progression of chronic intestinal inflamma- nal inflammation, CD1d-deficient TCR double-knock-
tion by enhancing IL-10 production. out (CD1DKO) mice were generated. As previously de-
scribed (Saubermann et al., 2000), CD1d knockout
(CD1KO) mice did not spontaneously develop colitisResults
(Figures 2A and 2C). In contrast, TCRKO, CD1DKO,
and B cell-deficient TCRKO (DKO) mice spontane-Upregulation of CD1d on GALT B Cells Is Associated
with the Development of Intestinal Inflammation ously developed intestinal inflammation. The kinetics of
intestinal inflammation development in CD1DKO miceThe MLN form a part of GALT, and the enlargement of
MLN is seen in TCRKO as well as IL2KO and IL10KO was very similar to that observed in TCRKO mice rather
than DKO mice; DKO mice developed colitis at anmice during the development of intestinal inflammation.
To examine whether there are differences in the B cell early age in comparison to CD1DKO mice (Figure 2A).
However, at 6 months of age, there was much morepopulations between these mice, MLN B cells from
these different mouse models of intestinal inflammation severe inflammation in the colon of CD1DKO mice
compared to TCRKO mice as indicated by the in-were examined. An enlargement of MLN was observed
in these mice (TCRKO, 38  5; IL10KO, 32  4; IL2KO, creased number of inflammatory cells and more thick-
ened colonic wall (Figures 2B–2F). Of note, ulceration57  12  106 cells) compared to wild-type mice (WT)
(5 0.7 106 cells). In the MLN cells, a marked increase characterized by loss of epithelium and fibrosis was
detected in 11.5% of CD1DKO mice with intestinalin the proportion of IgM	 cells was observed in TCRKO
mice (77.0  2.4%, n  18), and a lesser increase of inflammation (Figures 2E and 2F). In contrast, ulceration
was not detectable in the colon of TCRKO mice. Therethese cells was detected in IL10KO mice (40.2  1.7%,
n  10) compared to WT mice (30.8  4.6%, n  8) was a marked increase in the expression of the proin-
flammatory cytokine, IL-1, in the colonic mucosa of(Figure 1A). In contrast, the IgM	 B cells were virtually
absent in MLN of IL2KO mice. Interestingly, a distinct CD1DKO mice as compared to TCRKO mice (Figure
2G). Recently, signal transducer and activation of tran-expression pattern of CD1d was observed in MLN B cells
between TCRKO and IL10KO mice. A significant in- scription (STAT) 3 phosphorylation has been demon-
strated to participate in the perpetuation of intestinalcrease (p  0.001) of CD1d expression on MLN B cells
was detected in diseased TCRKO mice (fluorescent inflammation mediated by both Th1 and Th2 pathways,
and the activation of STAT3 correlates with the severitymean channel [FMC]  210.5  22.4, n  19) as com-
pared to WT mice (FMC  92.8  8.7, n  16) and of intestinal inflammation (Suzuki et al., 2001). Increased
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Figure 1. CD1d on Mucosal Associated B
Cells Is Upregulated after the Development
of Intestinal Inflammation
(A) The expression of CD3
 and IgM in MLN
cells from WT, TCRKO, IL10KO, and IL2KO
mice. The TCRKO (6 months of age), IL10KO
(6 months of age), and IL2KO (4 months of
age) mice exhibited intestinal inflammation.
(B) MLN cells from WT and CD1dKO mice
and diseased TCR and IL10KO mice were
stained with anti-CD1d and -B220 mAbs. The
figure shows CD1d expression on the gated
B220	 MLN cells.
(C) MLN cells from TCRKO mice, with and
without intestinal inflammation, and CD1dKO
mice were stained with anti-CD1d and -B220
mAbs. The figure shows CD1d expression on
the gated B220	 MLN cells.
(D) Cells from colonic LP of WT and diseased
TCRKO mice were stained with anti-CD1d
and -IgM mAbs. The figure shows CD1d ex-
pression on the gated IgM	 colonic LP cells.
(E) Cells from spleen of WT and diseased
TCRKO mice were stained with anti-CD1d
and -B220 mAbs.
(F) CD21 and CD62L expression on the gated
CD1dhiB220	 B cells from the spleen (SP) and
MLN of TCRKO mice. All of the mice shown
in (A)–(F) were 6 months of age.
STAT3 phosphorylation was observed in the colonic mu- tion, it is likely that CD1d is required for controlling the
progression rather than the initiation of intestinal inflam-cosa of TCRKO mice as compared to WT mice (Figure
2H). A greater increase in STAT3 activation was repro- mation. Therefore, B cells were transferred into the
DKO mice with mild to moderate disease. The pres-ducibly detected in CD1DKO mice as compared to
TCRKO mice (Figure 2H); the ratio of phosphorylated ence of intestinal inflammation was grossly confirmed
by opening the abdomen and measuring the circumfer-STAT3/STAT3 was 0.258  0.034 (n  7) in CD1DKO
mice and 0.132  0.023 (n  7) in TCRKO mice (p  ence of the distal colon as a marker for evaluating the
progression of intestinal inflammation (Figures 3B and0.01). These findings suggest that, although the onset
of intestinal inflammation is not changed in CD1DKO 3C). In DKO mice, the circumference of the distal
colon was found to progressively increase within a 44mice, the disease progresses rapidly in CD1DKO mice
presumably due to the lack of downregulation of the day period (from 12–18 weeks of age), indicating that
disease in the DKO mice progressed rapidly duringinflammatory cascade.
this period (Figure 3C). Transfer of B cells from TCRKO
mice was able to effectively inhibit the progression ofB Cells Upregulating CD1d Suppress the Progression
of Intestinal Inflammation intestinal enlargement in DKO mice (Figures 3B and
3C). In contrast, transfer of B cells from CD1DKO miceTo examine the role of B cells with high expression of
CD1d in the pathogenesis of intestinal inflammation, failed to suppress the exacerbation of intestinal enlarge-
ment. Histological examination also confirmed theB cells (Figure 3A) enriched from MLN of TCRKO or
CD1DKO mice were transferred into DKO mice that results obtained by evaluating the change of colonic
circumference. The intestinal inflammation as character-have no B cells and develop a more severe form of
colitis with an early onset at 8 weeks of age (Mizoguchi ized by thickening of the colonic mucosa with crypt
elongation and inflammatory cell infiltration was signifi-et al., 1997). Since increased CD1d expression on B cells
was found after the development of intestinal inflamma- cantly milder (p  0.001) in the DKO mice receiving
Immunity
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B cells with high expression of CD1d play an important
role in suppressing the progression of intestinal inflam-
mation.
Since intestinal inflammation in the TCRKO mice is
mediated by CD4	 T cells (Bhan et al.,1999), the role
of MHC class II-associated antigen presentation in the
regulatory properties of B cells was examined by trans-
ferring B cells from MHC II-deficient TCR double-
knockout (MHCDKO) mice into DKO mice. We ini-
tially observed that transfer of enriched B cells from
MHCDKO mice did not suppress the progression of
intestinal inflammation in DKO mice (data not shown).
However, it was also observed that there was a poor
expansion of B cells from MHCDKO mice in DKO
mice, and the absolute number of reconstituted B cells
within the recipient MLN was less than 3  105. By
increasing the number of transferred B cells (3 107) and
the frequency of injections (four times), MHC-deficient
B cells were also able to inhibit the progression of intesti-
nal enlargement in DKO mice (Figure 3C). In contrast,
B cells from CD1DKO mice failed to inhibit the disease
progression in the recipient DKO mice even with the
increased numbers of B cells and frequency of injections
(data not shown). These findings suggest that MHC
class II facilitates the expansion of B cells under chronic
inflammatory conditions. CD1d, rather than MHC class
II, may be effectively involved in the regulatory effect of
B cells on intestinal inflammation.
CD1d Expression Is Associated with Enhanced
IL-10 Production in MLN B Cells
Splenic CD1dhi B cells in the NZB/NZW strain, but not
the C57BL/6 strain, have been reported as a source of
IgM autoantibodies (Zeng et al., 2000). Since Igs partici-
pate in the suppression of the development of intestinalFigure 2. Absence of CD1d Leads to the Development of Severe
Intestinal Inflammation in TCRKO Mice inflammation in TCRKO mice (Mizoguchi et al., 1997),
Ig production in CD1DKO mice was examined. There(A) The incidence of intestinal inflammation in TCRKO (open cir-
cles), DKO (closed circles), CD1DKO (closed triangles), and was no significant difference in the serum Ig levels be-
CD1KO (open triangles) mice at various ages is shown. tween TCRKO and CD1DKO mice with intestinal in-
(B) Severity of intestinal inflammation of TCRKO and CD1DKO
flammation (Figure 4A). In addition, enzyme-linked im-mice at 6 months of age is shown. Each dot represents an individual
mune spot (ELISPOT) assays also showed no significantmouse. A significant difference (p  0.001) in the disease severity
difference in the number of MLN B cells secreting Igis observed between TCRKO and CD1DKO mice.
(C–F) Severity of colonic inflammation in CD1KO (C), TCRKO (D), and anti-tropomyosin autoantibodies between TCRKO
and CD1DKO (E and F) mice at 6 months of age is shown. More and CD1DKO mice with intestinal inflammation (Figure
severe colonic inflammation including ulceration was present in 4B and data not shown).
CD1DKO mice (E and F) than in TCRKO mice (D). ([C and D] X10,
Next, we screened the cytokine expression of freshly[E] X4, and [F] X20 objective).
isolated MLN cells by RNase protection assay (RPA).(G) Total RNA isolated from the colonic mucosa of WT, TCRKO,
and CD1DKO mice (6 months of age) was subjected to RPA for IL-10 mRNA was reproducibly detected in the MLN cells
the detection of IL-1. of TCRKO but not in DKO and CD1DKO mice (Fig-
(H) Proteins extracted from the colonic mucosa of WT, TCRKO, ure 4C). Furthermore, RT-PCR showed that IL-10 was
and CD1DKO mice (6 months of age) were immunoblotted with
detectable in the purified B220	 B cells from MLN ofanti-phospho-STAT3 (PY-STAT3) Ab. After stripping PY-STAT Ab,
diseased TCRKO mice (Figure 4D). Upregulation ofthe membrane was reprobed with anti-STAT3 Ab.
CD1d on these purified B220	 B cells was confirmed
by flow cytometric analysis (Figure 4E). In contrast, IL-
10 was not detectable in the purified B220	 B cells fromB cells from TCRKO mice in comparison to DKO
MLN of TCRKO mice without intestinal inflammationmice receiving B cells from CD1DKO mice or DKO
and diseased CD1DKO mice (Figure 4D). These find-mice without B cell transfer (Figures 3D and 3E). There
ings suggest that B cells are a source of IL-10 in thewas no significant difference between the number of
diseased TCRKO mice, and upregulation of CD1d isreconstituted B cells within the MLNs of recipient DKO
associated with enhanced IL-10 production by MLNmice after the cell transfer from either TCRKO or CD1-
DKO mice (Figure 3C). These findings indicate that MLN B cells.
Regulatory B Cells in Intestinal Inflammation
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Figure 3. Transfer of B Cells Expressing
CD1d Leads to Suppression of Colonic In-
flammation Progression in DKO Mice
(A) Representative flow cytometric result of
the enriched B cells used in the cell transfer
studies is shown. On average, 94.3  0.9%
of the preparations were IgM	B220	 cells
(range, 90.3%–96.9%). The IgMB220	 cells
were present at a range that varied from 2.7%
to 6.9%. CD3
	 cells, and NK-1.1	 cells rep-
resented less than 0.5% of the total cell prep-
arations.
(B–E) A small abdominal incision was made
in anesthetized DKO mice (12 weeks of
age) to determine the presence of intestinal
inflammation ([B] left panels). The colonic cir-
cumference was measured. MLN B cells
(1.5 107) from TCRKO and CD1DKO mice
were transferred into DKO mice 14 days
after the operation. After three injections of
MLN B cells (every 10 days), the recipient
DKO mice were sacrificed 10 days after
the last cell transfer, and the circumference
of the distal colon was measured. For the
transfer of B cells from MHCDKO mice, 3 
107 B cells were injected four times (every 7
days) into DKO mice. ([B] right panels)
Gross findings of the colon of the DKO
mice receiving the MLN B cells from TCRKO
(top panel) and CD1DKO (bottom panel)
mice are shown. (C) The figure summarizes
the results of the change in the colonic cir-
cumference (before and after the cell transfer)
of DKO mice receiving PBS alone or B cells
from TCRKO, CD1DKO, and MHCDKO
mice. The numbers next to the lines represent
the absolute numbers of reconstituted
IgM	B220	 B cells ( 106) in MLN of recipient
DKO mice. (D) Severity of intestinal inflam-
mation in DKO mice receiving PBS alone
or B cells from TCRKO, CD1DKO, or
MHCDKO mice is shown. Each dot repre-
sents an individual mouse. (E) Histological
findings (2.5  objective) of the distal colon of the WT mouse (top right) and DKO mouse transferred with PBS alone (bottom right) and
MLN B cells from TCRKO (top left, four individual colons) and CD1DKO (bottom left, four individual colons) mice are shown.
IL-10 Produced by MLN B Cells Regulates the proportion of the IgM	B220	 B cells in the MLN of
DKO mice after reconstitution and treatment with theProgression of Intestinal Inflammation by Directly
Downregulating Inflammatory Cascades combination of mAbs (anti-IL10R plus anti-IL10) and
with control Abs (Figures 5B and 5C). We also adminis-To determine whether IL-10 produced by CD1hi MLN
B cells is directly involved in the suppression of intestinal trated these mAbs into DKO mice without transferring
B cells. The in vivo neutralization of IL-10 activity didinflammation, DKO mice that had adoptively received
B cells from TCRKO mice were treated weekly with a not exacerbate the disease in the DKO mice (Figure
5D). This supports our contention that IL-10 producedcombination of anti-IL-10 receptor (R) and anti-IL-10
mAbs, a combination of mAbs that has been demon- by B cells is involved in the regulation of intestinal inflam-
mation in TCRKO mice.strated to efficiently neutralize in vivo activity of IL-10
(Asseman et al.,1999). The in vivo neutralization of IL- To further confirm these findings, IL-10-deficient
TCR double-knockout (IL10DKO) mice were gener-10 activity by the combination of these mAbs led to
progressive enlargement of the large intestine in the ated, and the B cells from these DKO mice were used
for cell transfer studies. Unlike B cells from TCRKODKO mice receiving B cells from TCRKO mice, indi-
cating that the suppressive activity of B cells in the mice, the transfer of B cells from IL10DKO mice was
unable to effectively inhibit the progression of intestinalintestinal inflammation is mediated by IL-10 (Figures 5A
and 5B). In contrast, the treatment with control Abs enlargement inDKO mice (Figure 6A). Taken together,
these findings indicate that IL-10 produced by MLNdid not affect the inhibitory activity of the adoptively
transferred B cells. Since IL-10 has been shown to pro- B cells is involved in suppressing the progression of
chronic intestinal inflammation.mote human B cell proliferation in vitro (Rousset et al.,
1992), we examined the MLN B cell populations in the Mechanistically, the intestinal inflammation of
TCRKO mice is mediated by the IL-4-dependent Th2recipient DKO mice with and without the treatment.
There was no obvious difference in the number and pathway as indicated by the suppression of intestinal
Immunity
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Figure 4. Absence of CD1d Affects IL-10
Production but Not Ig Secretion in TCRKO
Mice
(A) Serum samples were obtained from WT,
TCRKO, and CD1DKO mice (6 months of
age) and subjected to ELISA.
(B) MLN cells were obtained from WT,
TCRKO, and CD1DKO mice (6 months of
age). Number of Ig (IgM, IgA, and IgG)-secre-
ting cells per 1 105 MLN cells was evaluated
by ELISPOT assay.
(C) Total RNA extracted from single cell sus-
pension of MLN of WT, TCRKO, CD1DKO,
and DKO mice (6 months of age) was sub-
jected to RPA for the detection of IL-10. Data
are representative of three individual experi-
ments.
(D) B220	 cells were purified from MLN cells
of TCRKO mice with and without disease
and CD1DKO mice with disease (6 months
of age) by using MACS. RNA extracted from
5  105 cells (B220	IgM	  94.8%) was sub-
jected to RT-PCR using specific primers for
IL-10 and -actin (left panel). Data are repre-
sentative of four individual experiments. Flow
cytometric analysis shows that upregulation
of CD1d was found on the purified B220	
MLN B cells of diseased TCRKO mice but
not TCRKO mice without disease (right
panel).
inflammation in IL-4-deficient TCR double-knockout Inflammatory Conditions Associated with Intestinal
Inflammation Upregulate CD1d(IL4DKO) mice (Mizoguchi et al., 1999) and in TCRKO
mice treated with anti-IL-4 mAb (Iijima et al., 1999). Since Expression on B Cells
As upregulation of CD1d was not found in the MLNIL-10 can suppress the induction of Th2 responses
(Grunig et al., 1997; Cottrez et al., 2000), it is possible B cells of IL10KO mice (Figure 1), it could be suggested
that CD1d upregulation is mediated by IL-10. To exam-that B cells regulate intestinal inflammation in TCRKO
mice by downregulating Th2 polarization of immune re- ine this possibility, we generated IL-10-deficient TCR
double-knockout (IL10DKO) mice. As an unexpectedsponses. However, there was no detectable difference
in the IL-4 production by purified CD4	 colonic LP and result, like TCRKO mice, an upregulation of CD1d on
MLN B cells was also observed in association with de-MLN T cells from DKO mice with and without transfer
of B cells from TCRKO and IL10DKO mice (Figure velopment of intestinal inflammation in IL10DKO mice
(Figure 7A). These findings indicate that IL-10 is not6B). In contrast, transfer of MLN B cells from TCRKO,
but not IL10DKO mice, led to downregulation of IL-1 required for the upregulation of CD1d on MLN B cells
under chronic inflammatory conditions. No increase ofexpression and STAT3 activation in the colonic LP of
DKO mice (Figures 6C and 6D). Since IL-10 directly IL-4 production was observed in IL10KO mice (Davidson
et al., 1996), whereas the development of intestinal in-suppresses macrophage/monocyte-induced inflamma-
tory responses (Fiorentino et al., 1991; O’Farrell et al., flammation in TCRKO mice is associated with an in-
crease of IL-4, as well as IL-6, production (Mizoguchi1998; Riley et al., 1999), it is likely that once intestinal
inflammation is initiated, IL-10 directly suppresses the et al., 1999); these cytokines are known to be involved
in B cell activation and Ig class switching. However,inflammatory cascades resulting from upregulation of
IL-1 and activation of STAT3. upregulation of CD1d was also detectable on MLN
Regulatory B Cells in Intestinal Inflammation
225
Figure 5. Regulatory B Cell Function in Intes-
tinal Inflammation Is Inhibited by Neutraliza-
tion of IL-10 Activity
(A and B) The circumference of the colon was
measured by opening the abdomen of anes-
thetized DKO mice (12 weeks of age) (top
left inserts in each panel). Fourteen days after
the operation, the DKO mice were trans-
ferred with enriched MLN B cells (1.5  107)
from TCRKO mice. B cell transfers were per-
formed every 10 days (three times). A combi-
nation of mAbs (@IL10) specific for IL-10 (1
mg) and IL-10R (0.5 mg) (top panels in [A]) or
control rat immunoglobuins (1.5 mg) (bottom
panels in [A]) were injected intraperitoneally
the day after each B cell transfer. An addi-
tional dose of antibodies was administered 7
days after the final B cell transfer. The recipi-
ent mice were sacrificed on day 10 after the
final B cell transfer. The gross findings of the
colon of the recipient mice sacrificed on day
10 after the last cell transfer are shown as
large panels in (A). The results are summa-
rized in (B). The numbers next to the lines in
(B) represent absolute number of reconstitu-
ted IgM	B220	 B cells ( 106) in MLN of the
recipient DKO mice.
(C) Cells from MLN of the DKO mice with-
out (left panel) and with B cell transfer plus
administration of either control immunoglob-
ulins (middle panel) or @IL10 (right panel)
were stained with anti-CD21 and -IgM and
subjected to flow cytometric analysis.
(D) Change in the circumference of the colon
of DKO mice (without B cell transfer) with
and without administration of @IL10 is shown.
The same protocol omitting B cell transfer as
shown in (A) and (B) was used.
B cells of IL4DKO and IL-6-deficient TCR double- B cells from TCR  TCR () DKO mice, which have
no T cells, were also transferred into DKO mice. Theknockout (IL6DKO) mice with intestinal inflammation
(grade 4) (Figure 7A), indicating that neither IL-10, IL-4, transfer of splenic B cells from DKO mice also sup-
pressed the disease progression in the recipient DKOnor IL-6 is required for the upregulation of CD1d on MLN
B cells. mice (Figure 7C). In addition, the reconstituted B cells
in the recipient DKO mice exhibited upregulation ofIn our previous study, a significant decrease of intesti-
nal epithelial proliferation, a characteristic feature of in- CD1d compared to MLN B cells of DKO mice (Figure
7D). These findings indicate that chronic intestinal in-testinal inflammation, has been described in the recipi-
entDKO mice transferred with splenic B cells from WT flammatory conditions lead to upregulation of CD1d
even on splenic B cells from WT mice, which possessmice (Mizoguchi et al., 2000). Therefore, we examined
CD1d expression on the reconstituted B cells in the an ability to inhibit the progression of intestinal inflam-
mation in DKO mice.MLN of DKO mice receiving enriched B cells from
the spleens of WT mice. Increased CD1d expression
was clearly detectable on the WT-derived B cells recon- Discussion
stituted into the MLN of the recipient DKO mice with
intestinal inflammation (Figure 7B). In contrast, when B cells possess diverse immune functions, and both
regulatory and pathogenic roles of B cells have beenWT-derived splenic B cells were transferred into B cell-
deficient mice that do not develop intestinal inflamma- demonstrated in autoimmune diseases (Wolf et al., 1996;
Korganow et al., 1999; Fagarasan et al., 2000). A recenttion, upregulation of CD1d was not found in the reconsti-
tuted B cells in MLN of the recipient B cell-deficient study has shown that, like Th subsets, B cell subsets can
be distinguished by distinct cytokine secretion profilesmice (Figure 7B). Indeed, the transfer of splenic B cells
from WT mice inhibited the disease progression of the (Harris et al., 2000). Here, we have defined a GALT-
associated B cell subset that is characterized by upregu-recipient DKO mice (Figure 7C). To rule out the possi-
bility that inhibition of the disease progression is not lation of CD1d expression and enhanced production of
IL-10. This B cell subset appears after the developmentdue to the few contaminating T cells, purified splenic
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Figure 6. Transfer of MLN B Cells from
IL10DKO Mice Does Not Inhibit the Progres-
sion of Disease in DKO Mice
(A) Change of colonic circumference of DKO
mice before and after MLN B cell transfer from
TCRKO orIL10DKO mice is shown. The num-
bers next to the lines represent the absolute
numbers of reconstituted IgM	B220	 B cells
( 106) in the MLN of recipient DKO mice.
(B) CD4	 T cells were purified from MLN of
WT and DKO mice with and without B cell
transfer from TCRKO and IL10DKO mice.
The purified CD4	 T cells were stimulated
with plate-coated anti-TCR for 3 days. The
culture supernatants were subjected to
ELISA for the detection of IL-4.
(C) Total RNA was isolated from colonic mu-
cosa of DKO mice with and without B cell
transfer from TCRKO and IL10DKO mice
and analyzed by RPA.
(D) Proteins extracted from the colonic mu-
cosa of WT mice (lane 1) and DKO mice
without (lanes 2 and 3, the average [n  5]
ratio calculated by band density of phosphor-
ylated STAT3/density of STAT3, 0.348 
0.065) and with (lanes 4–7) B cell transfer from
either TCRKO (lanes 4 and 5, the average
ratio [n  5] was 0.141  0.031) or IL10DKO
mice (lanes 6 and 7, the average ratio [n  4]
was 0.380 0.090) were immunoblotted with
anti-phospho-STAT3 (PY-STAT3) Ab. After
stripping PY-STAT Ab, the membrane was
reprobed with anti-STAT3 Ab.
of chronic intestinal inflammation and participates in the cells resulting from chronic intestinal inflammation may
be involved in the production of IL-10. Alternatively, thesuppression of intestinal inflammation progression. This
B cell subset is detected in TCRKO mice where intesti- differentiation of regulatory B cells producing IL-10 may
depend on an interaction with CD1d-restricted T cells,nal inflammation is mediated by a Th2 pathway but not
in a Th1-mediated model of intestinal inflammation as- but CD1d crosslinking may not be required for IL-10
production. Increased translocation of nonpathogenicsociated with IL-10 deficiency. The increased expres-
sion of CD1d on splenic B cells from WT mice after bacteria from the intestinal lumen to MLN is associated
with the development of IL-4-associated intestinal in-transfer into diseased DKO mice also supports this
contention. flammation (Ceponis et al., 2000; Dombrowicz et al.,
2001), and a form of -anomeric glycolipid with phyto-CD1d binds a variety of lipid-containing antigens
(Moody et al., 1999; Burdin and Kronenberg, 1999), and sphingosine has been detected in certain bacteria (Ka-
wano et al., 1997). In the colitis induced by oral intakethe presentation of a glycolipid (-galactosyl ceramide)
by CD1d induces rapid activation of NKT cells (Kawano of 4% DSS, the CD1dhi B cells are detectable in the MLN
during the healing period (3 days after cessation of DSSet al., 1997). However, NKT cells are not present in
TCRKO mice (Taniguchi et al., 1996), indicating that intake) but not in the acute phase of inflammation during
DSS intake (our unpublished data). Since the transloca-the regulatory function of CD1dhi B cell subset is not
likely to be dependent on NKT cells. The presence of tion of enteric bacterial products into a host increases
in DSS-induced colitis due to direct damage of the epi-CD1d-restricted T cells without NK-1.1 expression has
recently been identified using CD1d tetramers (Ben- thelial layer by DSS, it is possible that bacteria-derived
glycolipids cause ligation of CD1d on a regulatory B celllagha et al., 2000; Matsuda et al., 2000), and CD1d-
restricted T cells that do not express an invariant TCR subset and/or CD1d-dependent expansion or activation
of a regulatory B cell subset.chain have been described (Behar and Cardell, 2000).
Therefore, it is possible that the regulatory effect of Igs have been shown to regulate the initiation of intes-
tinal inflammation by rapidly removing harmful self-anti-CD1dhi MLN B cells may be induced by the interaction
of NK-1.1 CD1-restricted T cells with CD1dhi B cells. gens in TCRKO mice (Mizoguchi et al., 1997). In this
study, we have identified a B cell subset that can regu-Ligation of CD1d results in a rapid and sustained pro-
duction of IL-10 (Colgan et al., 1999). CD1d is capable late intestinal inflammation through production of IL-10
after the onset of disease. The ability of B cells fromof binding a wide variety of lipid antigens including
-galactosyl ceramide, -galactosyl ceramide, which is TCRKO mice to inhibit the progression of intestinal
inflammation in DKO mice can be neutralized by theunable to activate NKT cells (Naidenko et al., 1999), and
phospholipids that are present in mammalian cells and administration of a combination of anti-IL-10 and -IL-
10R mAbs. Furthermore, B cell transfer from IL10DKOconsidered to be potential self-antigens (Gumperz et
al., 2000). Ligation of CD1d on B cells by self-phospho- mice is unable to effectively suppress the progression of
intestinal inflammation in DKO mice. These findingslipids or -anomeric glycolipid eluted from damaged
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Figure 7. Chronic Inflammatory Environment Leads to Upregulation of CD1d on WT-Derived B Cells
(A) MLN cells from WT, IL10DKO, IL4DKO, and IL6DKO mice (6 months of age) with mild to moderate colitis were stained with anti-CD1d
and -B220 mAbs. The figure shows CD1d expression on gated B220	 MLN cells.
(B) The figure shows CD1d expression on gated B220	 cells of MLNs from WT mice, DKO mice receiving splenic B cells from TCRKO
(  ) or WT (WT  ) mice, and B cell-deficient mice receiving splenic B cells from WT (WT  ) mice.
(C) Change of colonic circumference of DKO mice receiving PBS alone () or splenic B cells from WT mice (WT  ) or DKO mice
(  ) are shown. The numbers next to the lines represent the absolute numbers of reconstituted IgM	B220	 B cells ( 106) in the MLN
of recipient DKO mice.
(D) CD1d expression on gated MLN B220	 cells of DKO mice receiving splenic B cells from DKO mice (  ) and of donor DKO
mice () is shown.
1999). CD1dKO mice (F6 backcross to C57BL/6) (Behar et al., 1999)clearly demonstrate that IL-10 produced by B cells is
were obtained from Dr. M.J. Grusby, Harvard Medical School, Bos-involved in the regulation of a Th2-mediated intestinal
ton. IL-10 (F13 backcross to C57BL/6) and IL-6 (F7 backcross toinflammation. Recent studies have shown that initiation
C57BL/6) KO mice were purchased from Jackson Laboratory (Bar
of both polarized Th1 and Th2 responses can be regu- Harbor, Maine), and MHC class II KO (N5 backcross to C57BL/6)
lated by IL-10 (Grunig et al., 1997; Cottrez et al., 2000). mice were purchased from Taconic Farm. To generate CD1, IL10,
MHC, and IL6 DKO mice, CD1dKO, IL10KO, MHC-IIKO, and IL6KOHowever, administration of IL-10 does not alter estab-
mice were crossed with TCRKO mice. The screening was per-lished Th1 polarization in IL10KO mice (Davidson et al.,
formed by PCR using tail genomic DNA and the pairs of three primers1996). Furthermore, in vitro studies indicate that, al-
for distinguishing homozygous and heterozygous mice as previouslythough a high amount of IL-10 is produced by regulatory
described (Mizoguchi et al., 1997). All mice were maintained under
CD4	CD25	 T cells, IL-10 is not involved in the regula- specific pathogen free facilities at Massachusetts General Hospital.
tion of effector T cell functions (Thornton and Shevach, Known pathogenic organisms including the Helicobacter species
were not detectable in these mice.1998). Similarly, the transfer of regulatory B cells from
TCRKO mice does not change an established Th2 re-
B Cell Transfersponse in DKO mice. In contrast, the transfer of regu-
Cells were extracted from the pooled MLN or spleen of donor mice.latory B cells leads to downregulation of the inflamma-
For enrichment of MLN B cells, CD3
 (145-2C11), CD4 (RM4-4),tory cascade associated with IL-1 production and
CD11b (M1/70), and NK-1.1 (PK136) positive cells were depleted by
STAT3 activation. Indeed, IL-10 has been demonstrated using a magnetically activated cell sorting system (MACS, Miltenyi,
to directly suppress inflammatory responses (Fiorentino Auburn, CA). For enrichment of splenic B cells, depletion of CD117
(2B8) and CD11c (HL3) positive cells was also carried out. Afteret al., 1991; O’Farrell et al., 1998; Riley et al., 1999).
examining the purity of B220	IgM	 B cells by flow cytometric analy-Therefore, it is likely that IL-10 produced by B cells plays
sis, 1.5 107 enriched B cells from TCRKO, CD1DKO, IL10DKO,a regulatory role in chronic inflammatory conditions,
DKO, and WT mice and 3  107 enriched B cells from MHCDKOsuch as chronic colitis resembling human ulcerative coli-
mice were used for cell transfer studies. An abdominal incision was
tis associated with the TCRKO mice, by affecting in- made in anesthetized DKO mice (12 weeks of age) to determine
flammatory mediators and their effects rather than by the presence of intestinal inflammation. The circumference of the
colon was measured. The selected DKO mice that had developeddirectly affecting T cell functions.
mild to moderate intestinal inflammation (mice with a colonic cir-
cumference ranging from 6 mm to 13 mm) were used as recipientExperimental Procedures
mice. The recipient mice were injected intraperitoneally with B cells
14 days after the operation, and the B cell transfers were performedMice
TCRKO, DKO, IL4DKO, and DKO mice of C57BL/6 back- every 10 days (three times). The recipient mice were sacrificed 10
days after the last B cell transfer. Azide-free anti-IL10R (1B1.2) mAbsground have been described previously (Mizoguchi et al., 1997,
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